Enhanced efficacy of photodynamic therapy in combination with 3,75% imiquimod - a randomised, prospective , observer-blinded study in patients with actinic keratosis

Trial Profile

Enhanced efficacy of photodynamic therapy in combination with 3,75% imiquimod - a randomised, prospective , observer-blinded study in patients with actinic keratosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2014

At a glance

  • Drugs Aminolevulinic acid (Primary) ; Imiquimod (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top